Finasteride in 2026: Latest Research, FDA Updates, and What's Changed

Topical Finasteride Safety Warning. The FDA issued warnings about compounded topical finasteride spray products after 32 adverse events were reported between 2019 and 2024. The adverse events included sexual dysfunction, depression, and anxiety — the same types of side effects reported with oral finasteride.

Context matters: these are compounded products (NOT FDA-approved), the 32 reports over 5 years represent a tiny fraction of total users, and the reported side effects occur at comparable or higher rates with oral finasteride. The FDA's alert doesn't mean topical finasteride is dangerous — it means patients should be informed about potential risks, the same way they are with oral formulations. Full article

Gupta Pharmacovigilance Study. A 2026 Wiley publication by Gupta compared adverse event profiles between oral and topical finasteride using pharmacovigilance databases. The finding: oral finasteride generated significantly more adverse event reports than topical across all categories — sexual, psychological, and general. This provides the strongest population-level evidence to date that topical finasteride may have a more favorable side effect profile.

Caveat: pharmacovigilance data has inherent limitations (reporting bias, confounders, different user populations). It supports the hypothesis from the Piraccini Phase III trial that lower systemic exposure translates to fewer side effects, but doesn't prove causation.

Topical Dutasteride Phase II RCT. Panuganti et al. (Cureus 2025) published results from a Phase II randomized controlled trial of 135 men comparing topical dutasteride 0.05% against oral finasteride 1mg. The result: topical dutasteride was MORE effective than oral finasteride with a favorable safety profile.

This is early data from a small trial, but it's potentially significant. If confirmed in larger studies, topical dutasteride could offer the superior efficacy of dutasteride with the lower systemic exposure of topical delivery. Full article

EMA Acknowledges Suicidality Risk. The European Medicines Agency acknowledged in 2025 that finasteride can be associated with suicidality. This follows the FDA's 2022 addition of suicidal ideation and depression warnings to finasteride's labeling. The EMA's acknowledgment represents a convergence between the two major drug regulatory agencies on the psychological side effect question.

This doesn't change the overall risk-benefit assessment for most men — finasteride remains a well-tolerated medication with a favorable safety profile in clinical trials. But it reinforces the importance of monitoring mood and psychological wellbeing when on finasteride, and the importance of having access to mental health support if needed.

Updated PCPT Long-Term Data. The 20-year follow-up from the Prostate Cancer Prevention Trial continues to support finasteride's 25% reduction in prostate cancer incidence with no increase in cancer-specific mortality. The initial concern about higher-grade cancers has been attributed to detection bias. Full article

New Delphi Consensus Recommendations. Updated expert consensus guidelines continue to position oral finasteride as a first-line treatment for male androgenetic alopecia. The new recommendations also formally acknowledge topical finasteride as a reasonable alternative for men concerned about systemic exposure, while noting the more limited evidence base compared to oral.